Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label nilvadipine evaluation in mild to moderate Alzheimer's disease
2005-002744-25Phase 4Completed
- Sponsor
- Roskamp Institute
- Start
- Jan 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nilvadipine in Alzheimer's disease (AD), sponsored by Roskamp Institute. Primary endpoints: Completion of 6 weeks of nilvadipine treatment, Cognitive assessment and 2 more. Started Jan 2006; status: completed.
02
Drugs
nilvadipine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2005-002744-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002744-25.